Scientists at Tel Aviv University have created a cost-effective blood test capable of identifying lung cancer in stages two through four with a 93 percent success rate. By utilizing a specialized chip that bypasses the need for complex DNA sequencing, the diagnostic tool offers a streamlined approach to medical screening. This innovation is expected to facilitate earlier detection of the disease and allow healthcare providers to monitor the effectiveness of treatments in real time. Priced at approximately 60 dollars, the technology represents a significant advancement in oncology diagnostics, potentially improving patient outcomes by providing a more accessible and efficient method for tracking cancer progression.
Source : The Times of Israel
Photo : The Times of Israel
